CEO SUMMARY: Ameripath planned to go public in March. However, the stock market’s significant decline and further evaluation of the company’s business plan caused Wall Street underwriters to defer issuing the stock. Pathologists are curious as to whether AmeriPath’s “employee” business model influenced decisions about the public stock offering. UNDERWRITERS on Wall Street decided to […]
AmeriPath Stock Offering Pulled By Underwriters
Efforts to become first publicly traded pathology management firm stymied by market conditions
- By Robert Michel
- > From the Volume IV No. 6 - April 21, 1997 Issue
